Mind the GLP-1 Care Gap

  • White Paper
  • Noom for Work
  • 1 min read

Summary

Noom’s GLP-1 Care Gap white paper delves into the health and cost risks of the GLP-1 care gap, and explores how Noom’s programs enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications.

Mind the GLP-1 Care Gap

The obesity epidemic in America is causing chronic conditions like type 2 diabetes, heart disease, and hypertension to rise at an alarming rate, putting significant strain on healthcare systems. While GLP-1 medications have shown impressive clinical results in treating obesity, in order for them to be effective, they must be combined with lifestyle changes.

Noom’s 2024 retrospective study on its GLP-1 Companion program highlights the benefits of this integrated approach. The findings were life-changing:

  • Average weight loss of 11.8% (28.9 lbs.) for Noom users vs. 8.5% (19.5 lbs.) for non-Noom users.
  • Medication persistence of 12.26 months for Noom users vs. 8.91 months for non-Noom users.

Noom’s GLP-1 Care Gap white paper delves into the health and cost risks of the GLP-1 care gap, and explores how Noom’s programs enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications. Personalized support and comprehensive strategies can assist members in adopting healthier habits, achieving weight loss goals, and improve health outcomes, easing the strain on health systems and offering substantial cost benefits for organizations.

Download the white paper now and explore Noom’s GLP-1 Companion program for better health outcomes and cost savings.

Download the White Paper

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.